Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as AN9025 oral capsule
AN9025 · 1 trial · 2 indications
• Incidence, nature, and severity of adverse events according to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v5.0
| Arm | Type | Description |
|---|---|---|
| AN9025 Treatment | EXPERIMENTAL | Oral administration of AN9025 capsules |
| Name | Type | Description |
|---|---|---|
| AN9025 oral capsule | DRUG | AN9025 is a novel, oral, small molecule pan-RAS (ON) inhibitor that binds cyclophilin A (CypA) with a slow dissociation rate, forming a tri-complex with guanosine triphosphate (GTP) bound state of both mutant and wild-type RAS proteins. AN9025 exhibits potent anti-proliferative activity in RAS-addicted cancer cell lines, demonstrates favorable pharmacokinetics (PK), pharmacodynamics and an acceptable tolerability profile in vivo. |
Inclusion Criteria: 1. Aged ≥18 years old at the time of informed consent. 2. Able to provide informed consent voluntarily before any study-related activities and according to local guidelines. 3. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1. 4. Have an estimated life expe...
AN9025 is an investigational oral small molecule being developed for the treatment of advanced or metastatic solid tumors harboring RAS mutations. It is currently in Phase 1 clinical development and is not yet approved by the FDA.
AN9025 targets RAS, a protein that is frequently mutated in various cancers. By inhibiting RAS, the drug aims to interfere with signaling pathways that drive tumor growth, potentially offering a therapeutic option for patients with RAS-mutant solid tumors.
AN9025 is being developed by Adlai Nortye Ltd., a biopharmaceutical company listed on the stock exchange under the ticker symbol ANL. The company is conducting clinical trials to evaluate the safety and efficacy of this investigational drug.
AN9025 is currently in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities and is still undergoing clinical trials to assess its safety, tolerability, and preliminary efficacy in patients.
AN9025 is being evaluated in a Phase 1 clinical trial with the identifier NCT07252479. This trial is recruiting participants with advanced or metastatic solid tumors harboring RAS mutations, with an enrollment target of 118 patients, and is being conducted in the United States.
Yes, AN9025 oral capsule is the formulation of the drug AN9025. The oral capsule is the dosage form being tested in clinical trials, and the drug is referred to by the same name, AN9025, in both contexts.